Hong Kong Exchanges and Clearing Ltd stock faces scrutiny amid ex-economist Ba Shusong's sudden disappearance and HKEX anti-corruption probe

Hong Kong Exchanges and Clearing Ltd, the operator of one of Asia's largest stock exchanges, is under the spotlight due to the abrupt disappearance of its prominent former economist Ba Shusong. Ba, who served as HKEX's first chief China economist from 2015 and later as a part-time adviser until late 2025, has not been seen publicly since early March 2026. This comes just after Hong Kong's Independent Commission Against Corruption (ICAC) and Securities and Futures Commission (SFC) launched a joint operation on March 10 targeting IPO market irregularities. US investors should watch closely as HKEX bridges China and global markets, with any governance issues potentially rippling into cross-border listings and trading volumes that affect international portfolios.

As of: 26.03.2026

By Elena Vasquez, Senior Asia Markets Analyst: Ba Shusong's silence underscores persistent governance risks at HKEX, a critical gateway for US funds accessing Chinese equities amid geopolitical tensions.

Ba Shusong's Disappearance Sparks Governance Concerns at HKEX

Ba Shusong, a high-profile figure known for advocating yuan internationalization and HKEX's role in linking mainland China to global finance, went silent after his last Weibo post on March 11, 2026. By mid-March, he became unreachable, with his Facebook inactive since March 9. Sources familiar with the matter confirmed to Caixin Global that the economist, academic, and frequent speaker on Hong Kong's financial bridge to the world has not appeared publicly recently.

HKEX confirmed on March 24 that Ba was no longer affiliated, but the timing aligns suspiciously with the ICAC-SFC probe into IPO irregularities. Ba's tenure made him the public face of HKEX, providing think-tank support for initiatives like Stock Connect programs that facilitate northbound and southbound trading between Hong Kong and mainland exchanges.

For US investors, this episode highlights operational risks at HKEX. The exchange handles dual listings for many US-listed Chinese firms delisting or seeking secondary quotes, making any scandal a potential drag on liquidity and confidence.

Regulatory Probe Targets IPO Irregularities on HKEX Platform

The joint ICAC-SFC operation launched on March 10 focuses on irregularities in the IPO market, a core revenue driver for HKEX through listing fees and related services. While no direct link to Ba has been confirmed, the probe's timing fuels speculation about broader compliance issues at the exchange.

HKEX has been expanding its listings, with new securities like EFUND A SEMICON (03486) set to trade on March 26, GLOBAL CHI-10K (02935) on March 25, and others in recent days. This activity underscores HKEX's vibrancy, but any corruption taint could deter issuers, especially those eyeing Hong Kong as a safer harbor amid US-China tensions.

US investors care because HKEX listings often serve as alternatives for Chinese tech and biotech firms facing SEC scrutiny. A cleaner regulatory environment bolsters HKEX's appeal, but probes like this introduce uncertainty.

HKEX's Broader Operations Amid China Market Pressures

HKEX continues robust activity, clearing OTC derivatives with initial margin at $2.10 billion in Q4 2025, flat quarter-on-quarter but up 34% year-on-year. SEOCH reported 40.73% of participant cash held as securities, up from prior periods, indicating strong collateral management.

New listings and rights offerings, such as PAC LEGEND RTS (08599) and DJ HAIYU B2903 (40136) on March 25, show resilience. HSBC's waiver for contingent convertible securities on March 25 further demonstrates HKEX's flexibility for major issuers.

For US portfolios heavy in Asian exposure, HKEX's stability is key. It powers programs like Shanghai-Hong Kong Stock Connect, channeling billions in flows that indirectly influence US-listed ADRs.

US Investor Relevance: Gateway to China with Rising Risks

US investors allocate to HKEX stock for its monopoly-like position in Hong Kong trading and clearing, offering diversified revenue from fees, data services, and connect programs. Amid US-China decoupling talks, HKEX remains a neutral venue for mainland firms raising capital without full US regulatory hurdles.

Ba's case amplifies risks from Beijing's influence over Hong Kong finance. US funds must weigh HKEX's growth potential against potential delisting pressures or reduced mainland IPO pipelines due to regulatory crackdowns.

With volatility in HSI futures and tech names like Kuaishou declining, HKEX stock sensitivity to China sentiment makes it a barometer for regional recovery, relevant for US ETFs tracking Asia ex-Japan.

Risks and Open Questions Surrounding HKEX

Key risks include escalation of the IPO probe, potentially implicating more HKEX personnel or processes. If Ba's silence ties to official investigations, it could erode trust in HKEX's oversight, impacting listing appeal.

Macro headwinds like unchanged China Loan Prime Rate at 3.00% signal tepid stimulus, pressuring trading volumes. Geopolitical strains may accelerate mainland firms' shift to domestic exchanges, shrinking HKEX's share.

US investors face ADR conversion risks and potential sanctions spillover. Without swift clarity from HKEX, volatility could persist, advising caution on position sizing.

HKEX's Strategic Positioning and Future Outlook

Despite challenges, HKEX pursues innovations like AI+ and Finance+ alignments with national strategies, as noted by commentators. Its role in clearing and new product launches positions it for long-term growth in derivatives and ETFs.

For US observers, monitoring HKEX reveals China market pulses. Balanced exposure via diversified funds mitigates single-event risks like Ba's case.

Overall, while the stock navigates scrutiny, its infrastructure dominance endures.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.